Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 4 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Epsom salt — MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Application NDA020488 (NDA)
Atropen — ATROPINE SULFATE
Application NDA021146 (NDA)
Cancidas — CANCIDAS
Application NDA021227 (NDA)
Faslodex — FASLODEX
Application NDA021344 (NDA)
Atropen — ATROPEN
Application NDA017106 (NDA)
Epsom salt — MAGNESIUM SULFATE IN PLASTIC CONTAINER
Application NDA020309 (NDA)
Naropin — NAROPIN
Application NDA020533 (NDA)
Bloxiverz — BLOXIVERZ
Application NDA204078 (NDA)
Atropen — ATROPINE SULFATE
Application NDA206289 (NDA)
Cancidas — CASPOFUNGIN ACETATE
Application NDA206110 (NDA)
Atropen — ISOPTO ATROPINE
Application NDA208151 (NDA)
Bloxiverz — NEOSTIGMINE METHYLSULFATE
Application NDA203629 (NDA)
Atropen — ATROPINE (AUTOINJECTOR)
Application NDA212319 (NDA)
Atropen — ATROPINE SULFATE
Application NDA209260 (NDA)
Faslodex — FULVESTRANT
Application NDA210063 (NDA)
Faslodex — FULVESTRANT
Application NDA210326 (NDA)
Atropen — ATROPINE SULFATE
Application NDA214652 (NDA)
Atropen — ATROPINE SULFATE
Application NDA213581 (NDA)
Esmeron — ROCURONIUM BROMIDE
Application NDA219108 (NDA)
Esmeron — ROCURONIUM BROMIDE
Application NDA217472 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)